TrialPloS one2020

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer.

Cynthia Huang Bartlett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.